These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1009 related articles for article (PubMed ID: 23460414)
21. Prognostic factors and outcome in relapsed multiple myeloma after nonmyeloablative allo-SCT: a single center experience. Minnema MC; van Dorp S; van de Donk NW; Schouten F; Kersten MJ; Coenen JL; Schouten H; Zweegman S; Schaafsma R; Lokhorst HM Bone Marrow Transplant; 2011 Feb; 46(2):244-9. PubMed ID: 20400982 [TBL] [Abstract][Full Text] [Related]
22. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma. Kröger N; Badbaran A; Zabelina T; Ayuk F; Wolschke C; Alchalby H; Klyuchnikov E; Atanackovic D; Schilling G; Hansen T; Schwarz S; Heinzelmann M; Zeschke S; Bacher U; Stübig T; Fehse B; Zander AR Biol Blood Marrow Transplant; 2013 Mar; 19(3):398-404. PubMed ID: 23078786 [TBL] [Abstract][Full Text] [Related]
23. Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation. Auner HW; Szydlo R; van Biezen A; Iacobelli S; Gahrton G; Milpied N; Volin L; Janssen J; Nguyen Quoc S; Michallet M; Schoemans H; El Cheikh J; Petersen E; Guilhot F; Schönland S; Ahlberg L; Morris C; Garderet L; de Witte T; Kröger N; Bone Marrow Transplant; 2013 Nov; 48(11):1395-400. PubMed ID: 23708704 [TBL] [Abstract][Full Text] [Related]
24. Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens. Abou-Mourad YR; Lau BC; Barnett MJ; Forrest DL; Hogge DE; Nantel SH; Nevill TJ; Shepherd JD; Smith CA; Song KW; Sutherland HJ; Toze CL; Lavoie JC Bone Marrow Transplant; 2010 Feb; 45(2):295-302. PubMed ID: 19597425 [TBL] [Abstract][Full Text] [Related]
25. Autologous and allogeneic transplantation for multiple myeloma at a single centre. Couban S; Stewart AK; Loach D; Panzarella T; Meharchand J Bone Marrow Transplant; 1997 Apr; 19(8):783-9. PubMed ID: 9134169 [TBL] [Abstract][Full Text] [Related]
26. Comparable outcomes between unrelated and related donors after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation in patients with high-risk multiple myeloma. El-Cheikh J; Crocchiolo R; Boher JM; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Castagna L; Lemarie C; De Colella JM; Coso D; Bouabdallah R; Chabannon C; Blaise D Eur J Haematol; 2012 Jun; 88(6):497-503. PubMed ID: 22385049 [TBL] [Abstract][Full Text] [Related]
27. Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC. Chevallier P; Labopin M; Socie G; Rubio MT; Blaise D; Vigouroux S; Huynh A; Michallet M; Bay JO; Maury S; Yakoub-Agha I; Fegueux N; Deconinck E; Contentin N; Maillard N; Bulabois CE; Francois S; Oumedaly R; Raus N; Mohty M Eur J Haematol; 2015 May; 94(5):449-55. PubMed ID: 25238651 [TBL] [Abstract][Full Text] [Related]
28. Incidence of Viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients. Satwani P; Baldinger L; Freedman J; Jacobson JS; Guerra J; van de Ven C; Morris E; Garvin J; George D; Bradley MB; Bhatia M; Tallamy B; Schwartz J; Jin Z; Cairo MS Biol Blood Marrow Transplant; 2009 Dec; 15(12):1587-95. PubMed ID: 19896083 [TBL] [Abstract][Full Text] [Related]
29. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival. Dhakal B; D'Souza A; Martens M; Kapke J; Harrington AM; Pasquini M; Saber W; Drobyski WR; Zhang MJ; Hamadani M; Hari PN Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):379-86. PubMed ID: 27160644 [TBL] [Abstract][Full Text] [Related]
30. Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Park S; Labopin M; Yakoub-Agha I; Delaunay J; Dhedin N; Deconinck E; Michallet M; Robin M; De Revel T; Bernard M; Vey N; Lioure B; Lapusan S; Tabrizi R; Bourhis JH; Huynh A; Beguin Y; Socié G; Dreyfus F; Fenaux P; Mohty M Eur J Haematol; 2013 May; 90(5):355-64. PubMed ID: 23320648 [TBL] [Abstract][Full Text] [Related]
31. Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. El-Cheikh J; Vazquez A; Crocchiolo R; Furst S; Calmels B; Castagna L; Lemarie C; Granata A; Ladaique P; Oudin C; Faucher C; Chabannon C; Blaise D Am J Hematol; 2012 Dec; 87(12):1074-8. PubMed ID: 22911907 [TBL] [Abstract][Full Text] [Related]
32. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. Pérez-Simón JA; Díez-Campelo M; Martino R; Brunet S; Urbano A; Caballero MD; de León A; Valcárcel D; Carreras E; del Cañizo MC; López-Fidalgo J; Sierra J; San Miguel JF Br J Haematol; 2005 Aug; 130(3):394-403. PubMed ID: 16042689 [TBL] [Abstract][Full Text] [Related]
33. Efficacy of up-front treatment with a double stem cell transplantation in multiple myeloma. Eom KS; Min CK; Lee S; Kim YJ; Kim SY; Kim HJ; Lee JW; Min WS; Kim CC Jpn J Clin Oncol; 2006 Jul; 36(7):432-8. PubMed ID: 16782727 [TBL] [Abstract][Full Text] [Related]
34. Allo-SCT for multiple myeloma in the era of novel agents: a retrospective study on behalf of Swiss Blood SCT. Gerull S; Stern M; Ben Aissa A; Manz MG; Schanz U; Stussi G; Chalandon Y; Passweg J; Mohty B Bone Marrow Transplant; 2013 Mar; 48(3):408-13. PubMed ID: 22941381 [TBL] [Abstract][Full Text] [Related]
35. Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC. Tessoulin B; Ceballos P; Chevallier P; Blaise D; Tournilhac O; Gauthier J; Maillard N; Tabrizi R; Choquet S; Carras S; Ifrah N; Guillerm G; Mohty M; Tilly H; Socie G; Cornillon J; Hermine O; Daguindau É; Bachy E; Girault S; Marchand T; Oberic L; Reman O; Leux C; Le Gouill S Bone Marrow Transplant; 2016 Sep; 51(9):1184-90. PubMed ID: 27111043 [TBL] [Abstract][Full Text] [Related]
36. Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion. Todisco E; Castagna L; Sarina B; Mazza R; Anastasia A; Balzarotti M; Banna G; Tirelli U; Soligo D; Santoro A Eur J Haematol; 2007 Apr; 78(4):322-9. PubMed ID: 17253967 [TBL] [Abstract][Full Text] [Related]
37. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. Alvarez I; Sureda A; Caballero MD; Urbano-Ispizua A; Ribera JM; Canales M; García-Conde J; Sanz G; Arranz R; Bernal MT; de la Serna J; Díez JL; Moraleda JM; Rubió-Félix D; Xicoy B; Martínez C; Mateos MV; Sierra J Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515 [TBL] [Abstract][Full Text] [Related]
38. Tandem autologous non-myeloablative allogeneic transplantation in patients with multiple myeloma relapsing after a first high dose therapy. Karlin L; Arnulf B; Chevret S; Ades L; Robin M; De Latour RP; Malphettes M; Kabbara N; Asli B; Rocha V; Fermand JP; Socie G Bone Marrow Transplant; 2011 Feb; 46(2):250-6. PubMed ID: 20400980 [TBL] [Abstract][Full Text] [Related]
39. [Comparison of autologous and allogeneic hematopoietic stem cell transplantation for 140 patients with de novo acute leukemia in first complete remission]. Wang HH; Feng SZ; Wang M; Wei JL; Jiang EL; Zhang L; Huang Y; Zhou SY; Liu QG; Qiu LG; Han MZ; Yan WW Zhonghua Xue Ye Xue Za Zhi; 2004 Jul; 25(7):389-92. PubMed ID: 15355688 [TBL] [Abstract][Full Text] [Related]
40. Long-term follow-up of an intensified myeloablative conditioning regimen with in vivo T cell depletion followed by allografting in patients with advanced multiple myeloma. Kröger N; Einsele H; Derigs G; Wandt H; Krüll A; Zander A Biol Blood Marrow Transplant; 2010 Jun; 16(6):861-4. PubMed ID: 20139025 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]